News
COSM
0.6700
-0.56%
-0.0038
Weekly Report: what happened at COSM last week (0429-0503)?
Weekly Report · 1d ago
Weekly Report: what happened at COSM last week (0422-0426)?
Weekly Report · 04/29 12:16
Weekly Report: what happened at COSM last week (0415-0419)?
Weekly Report · 04/22 12:00
Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules
Benzinga · 04/19 20:48
COSMOS HEALTH INC - RECEIVES NASDAQ NOTICE ON LATE FILING OF ITS FORM 10-K
Reuters · 04/19 20:36
COSMOS HEALTH INC - INTENDS TO RESOLVE DEFICIENCY AND REGAIN COMPLIANCE WITH NASDAQ LISTING RULES
Reuters · 04/19 20:36
Weekly Report: what happened at COSM last week (0408-0412)?
Weekly Report · 04/15 11:50
Cosmos Health Inc <COSM.OQ> expected to post a loss of 20 cents a share - Earnings Preview
Cosmos Health Inc expected to post a loss of 20 cents a share - Earnings Preview. The company is expected to report revenue of $13.75 million. The one available analyst rating on the shares is "buy" for the company. Cosmos Health Inc COSM.OQ is scheduled to report April 11.
Reuters · 04/09 20:02
Weekly Report: what happened at COSM last week (0401-0405)?
Weekly Report · 04/08 11:56
Weekly Report: what happened at COSM last week (0325-0329)?
Weekly Report · 04/01 11:53
Weekly Report: what happened at COSM last week (0318-0322)?
Weekly Report · 03/25 11:57
Cosmos Health Commences Development Of Cloudscreen 2.0, The New Iteration Of Its Next Generation AI Drug Repurposing Platform
Cosmos Health Inc. Announced the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence drug repurposing platform. The integration of AI and machine learning will help unlock unknown actions of existing drugs on the market. Cosmos Health completed the acquisition of cloudscreen in January 2024.
Benzinga · 03/21 13:48
Cosmos Health To Receive Regulatory Approval For C-Scrub Disinfectant In The UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU; No Financial Terms Of Purchase Order Disclosed
Cosmos Health is in the final stages of securing regulatory approval to sell its disinfectant hand soap, C-Scrub Wash 4% CHG, in the United Kingdom. The company expects to enter into agreements to supply the National Health Service in the UK. C- scrub is ideal for routine hand disinfection and targets a wide range of microbes.
Benzinga · 03/19 14:13
Cosmos Health secures regulatory approval to sell Sky Premium Life products in UAE
Cosmos Health secures regulatory approval to sell Sky Premium Life products in UAE. The company says it has also received inaugural purchase orders for the vitamins and food supplements in the United Arab Emirates market. COSM says it expects to secure exclusive distribution agreement in the UAE.
Seeking Alpha · 03/18 13:49
Weekly Report: what happened at COSM last week (0311-0315)?
Weekly Report · 03/18 11:55
Weekly Report: what happened at COSM last week (0304-0308)?
Weekly Report · 03/11 11:50
Weekly Report: what happened at COSM last week (0226-0301)?
Weekly Report · 03/04 11:54
Despite Disappointing Results, Henry Schein Looks Appealing Moving Forward
Seeking Alpha · 02/28 19:41
Weekly Report: what happened at COSM last week (0219-0223)?
Weekly Report · 02/26 12:11
As Trading Frenzies Grip Penny Stocks, Criticism of Nasdaq Grows
A growing number of stocks with a low share price are trading billions of shares a day. Some companies do reverse splits to stay listed on the Nasdaq stock exchange. Critics say Nasdaq faces a conflict of interest. The number of sub-$1 stocks has swelled in recent years.
The Wall Street Journal · 02/23 04:00
More
Webull provides a variety of real-time COSM stock news. You can receive the latest news about Cosmos Health Inc. through multiple platforms. This information may help you make smarter investment decisions.
About COSM
Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.